MedTrace Logo

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2026-04-09

No results posted yet for this study

Summary

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

Conditions

Interventions

DRUG

Tozorakimab

The drug will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-26
Primary Completion
2027-06-24
Completion
2028-03-16
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Chile
  • China
  • France
  • Greece
  • Hungary
  • India
  • Israel
  • Italy
  • Japan
  • Peru
  • Philippines
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06932263 on ClinicalTrials.gov